Across TCGA pan-cancer cohorts, MAK16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MAK16 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher MAK16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAK16 expression acts as an unfavorable survival marker.

SCLC and LGG are the cancer types where MAK16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LGG	OS	Median	All	0.306	0.810	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MAK16 tumor-vs-normal RNA expression · all MAK16 data types